 [1m([0morchestrator-hospitalization-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes TIGECYCLINE increase or decrease the risk of hospitalization?[0m
 [1m([0morchestrator-hospitalization-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hospitalization-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does TIGECYCLINE increase or decrease the risk of hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hospitalization-TIGECYCLINE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes TIGECYCLINE increase or decrease the risk of hospitalization?[0m
 [1m([0morchestrator-hospitalization-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hospitalization-TIGECYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes TIGECYCLINE increase or decrease the risk of hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does TIGECYCLINE increase or decrease the risk of hospitalization?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"tigecycline"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: TIGECYCLINE: clinical_studies_table: [0m[1;31m<[0m[1;31mtable[0m[31m [0m[31mID[0m[31m=[0m[31m"t11"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"100[0m[31m%"[0m[31m><caption [0m[31mID[0m[31m=[0m[31m"G27e24559[0m[31m-6ed6-49f7-a922-9571f94945ca"[0m[31m>Table [0m[1;31m10[0m[31m. Post-hoc Analysis of Clinical Cure Rates in Patients with [0m
[31mCommunity-Acquired Bacterial Pneumonia Based on Risk of Mortality<sup>a<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mcaption[0m[31m><colgroup><col [0m[31malign[0m[31m=[0m[31m"left"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"25[0m[31m%"[0m[31m/[0m[31m><col [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"25[0m[31m%"[0m[31m/[0m[31m><col [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"25[0m[31m%"[0m[31m/[0m[31m><col [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mwidth[0m[31m=[0m[31m"25[0m[31m%"[0m[31m/[0m[31m><[0m[31m/[0m[31mcolgroup[0m[31m><thead><tr><th/><th>Tigecycline for injection<[0m[31m/[0m[31mth[0m[31m><th>Levofloxacin<[0m[31m/[0m[31mth[0m[31m><th/><[0m[31m/[0m[31mtr[0m[31m><tr><th/><th>n/N [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m <[0m[31m/[0m[31mth[0m[31m><th>n/N [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m <[0m[31m/[0m[31mth[0m[31m><th>[0m[1;31m95[0m[31m% [0m
[31mCI<sup>b<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mth[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mthead[0m[31m><tfoot><tr><td [0m[31mcolspan[0m[31m=[0m[31m"4"[0m[31m><sup>a<[0m[31m/[0m[31msup[0m[31m TIGECYCLINE: clinical_studies_table: > Patients at higher risk of death include patients with any one of the following: [0m
[31m&#x2265;[0m[1;31m50[0m[31m year of age; PSI score &#x2265;[0m[1;31m3[0m[31m; or bacteremia due to <content [0m[31mstyleCode[0m[31m=[0m[31m"italics"[0m[31m>Streptococcus pneumoniae<[0m[31m/[0m[31mcontent[0m[31m><paragraph><sup>b<[0m[31m/[0m[31msup[0m[31m> [0m[1;31m95[0m[31m% confidence interval for the treatment [0m
[31mdifference<[0m[31m/[0m[31mparagraph[0m[31m><paragraph><sup>c<[0m[31m/[0m[31msup[0m[31m> After at least [0m[1;31m3[0m[31m days of intravenous therapy, a switch to oral levofloxacin [0m[1;31m([0m[1;31m500[0m[31m mg daily[0m[1;31m)[0m[31m was permitted for both treatment arms in Study [0m[1;31m1[0m[31m. TIGECYCLINE: [0m
[31mclinical_studies_table: paragraph><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtfoot[0m[31m><tbody><tr><td>Study [0m[1;31m1[0m[31m<sup>c<[0m[31m/[0m[31msup[0m[31m><[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> CE <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Higher risk [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Yes <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m93[0m[31m/[0m[1;31m103[0m[31m [0m[1;31m([0m[1;31m90.3[0m[1;31m)[0m[31m [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m84[0m[31m/[0m[1;31m102[0m[31m [0m[1;31m([0m[1;31m82[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m4[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-2.3[0m[31m, [0m[1;31m18.2[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> No <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m32[0m[31m/[0m[1;31m35[0m[31m [0m[1;31m([0m[1;31m91.4[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m52[0m[31m/[0m[1;31m54[0m[31m [0m[1;31m([0m[1;31m96.3[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-20.8[0m[31m, [0m[1;31m7[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m1[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> c-mITT [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Higher risk <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Yes <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m111[0m[31m/[0m[1;31m142[0m[31m [0m[1;31m([0m[1;31m78.2[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m100[0m[31m/[0m[1;31m134[0m[31m [0m[1;31m([0m[1;31m74.6[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-6.9[0m[31m, [0m[1;31m14[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> No <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m38[0m[31m/[0m[1;31m49[0m[31m [0m[1;31m([0m[1;31m77[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m6[0m[1;31m)[0m[31m [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m58[0m[31m/[0m[1;31m69[0m[31m [0m[1;31m([0m[1;31m84.1[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-22.8[0m[31m, [0m[1;31m8[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m7[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td>Study [0m[1;31m2[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> CE <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Higher risk <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Yes <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m95[0m[31m/[0m[1;31m107[0m[31m [0m[1;31m([0m[1;31m88[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m8[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m68[0m[31m/[0m[1;31m85[0m[31m [0m[1;31m([0m[1;31m80[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-2.2[0m[31m, [0m[1;31m20.3[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> No <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m33[0m[31m/[0m[1;31m37[0m[31m [0m[1;31m([0m[1;31m89.2[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m48[0m[31m/[0m[1;31m51[0m[31m [0m[1;31m([0m[1;31m94.1[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-21.1[0m[31m, [0m[1;31m8[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m6[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> c-mITT <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Higher risk <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m> <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> Yes [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m112[0m[31m/[0m[1;31m134[0m[31m [0m[1;31m([0m[1;31m83.6[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m93[0m[31m/[0m[1;31m120[0m[31m [0m[1;31m([0m[1;31m77.5[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-4.2[0m[31m, [0m[1;31m16.4[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td> No <[0m[31m/[0m[31mtd[0m[31m><td [0m
[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m58[0m[31m/[0m[1;31m69[0m[31m [0m[1;31m([0m[1;31m84[0m[31m. TIGECYCLINE: clinical_studies_table: [0m[1;31m1[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m70[0m[31m/[0m[1;31m80[0m[31m [0m[1;31m([0m[1;31m87.5[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"middle"[0m[31m>[0m[1;31m([0m[1;31m-16.2[0m[31m, [0m[1;31m8[0m[31m. TIGECYCLINE: [0m
[31mclinical_studies_table: [0m[1;31m8[0m[1;31m)[0m[31m <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[1;31m>[0m[31m         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: warnings_and_cautions: [0m[1;31m6[0m[31m [0m[1;31m)[0m[31m Tooth Discoloration and Enamel Hypoplasia: The use of tigecycline for injection during tooth development [0m[1;31m([0m[31mlast half of pregnancy, infancy, and [0m
[31mchildhood to the age of [0m[1;31m8[0m[31m years[0m[1;31m)[0m[31m may cause permanent discoloration of the teeth [0m[1;31m([0m[31myellow-gray-brown[0m[1;31m)[0m[31m and enamel hypoplasia. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m Inhibition of Bone Growth: The use of tigecycline for injection [0m
[31mduring the second and third trimester of pregnancy, infancy, and childhood up to the age of [0m[1;31m8[0m[31m years may cause reversible inhibition of bone growth. [0m[1;31m([0m[31m [0m[1;31m5.8[0m[31m [0m[1;31m)[0m[31m Clostridium difficile associated Diarrhea [0m
[1;31m([0m[31mCDAD[0m[1;31m)[0m[31m: evaluate if diarrhea occurs. [0m[1;31m([0m[1;31m5.9[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5.1[0m[31m All-Cause Mortality An increase in all-cause mortality has been observed in a meta-analysis of Phase [0m[1;31m3[0m[31m and [0m[1;31m4[0m[31m clinical trials in tigecycline for [0m
[31minjection-treated patients versus comparator-treated patients. TIGECYCLINE: warnings_and_cautions: In all [0m[1;31m13[0m[31m Phase [0m[1;31m3[0m[31m and [0m[1;31m4[0m[31m trials that included a comparator, death occurred in [0m[1;31m4.0[0m[31m% [0m[1;31m([0m[1;31m150[0m[31m/[0m[1;31m3788[0m[1;31m)[0m[31m of [0m
[31mpatients receiving tigecycline for injection and [0m[1;31m3.0[0m[31m% [0m[1;31m([0m[1;31m110[0m[31m/[0m[1;31m3646[0m[1;31m)[0m[31m of patients receiving comparator drugs. In a pooled analysis of these trials, based on a random effects model by trial weight, the [0m
[31madjusted risk difference of all-cause mortality was [0m[1;31m0.6[0m[31m% [0m[1;31m([0m[1;31m95[0m[31m% CI [0m[1;31m0.1[0m[31m, [0m[1;31m1.2[0m[1;31m)[0m[31m between tigecycline for injection and comparator-treated patients. An analysis of mortality in all trials conducted for [0m
[31mapproved indications [0m[1;31m([0m[31mcSSSI, cIAI, and CABP[0m[1;31m)[0m[31m, including post-market trials showed an adjusted mortality rate of [0m[1;31m2.5[0m[31m% [0m[1;31m([0m[1;31m66[0m[31m/[0m[1;31m2640[0m[1;31m)[0m[31m for tigecycline and [0m[1;31m1.8[0m[31m% [0m[1;31m([0m[1;31m48[0m[31m/[0m[1;31m2628[0m[1;31m)[0m[31m for comparator, respectively. [0m
[31mTIGECYCLINE: warnings_and_cautions: The adjusted risk difference for mortality stratified by trial weight was [0m[1;31m0.6[0m[31m% [0m[1;31m([0m[1;31m95[0m[31m% CI [0m[1;31m0.0[0m[31m, [0m[1;31m1.2[0m[1;31m)[0m[31m. The cause of this mortality difference has not been established. [0m
[31mGenerally, deaths were the result of worsening infection, complications of infection or underlying co-morbidities. Tigecycline for injection should be reserved for use in situations when alternative [0m
[31mtreatments are not suitable [0m[31m . [0m[1;31m5.2[0m[31m Mortality Imbalance and Lower Cure Rates in Hospital-Acquired Pneumonia A trial of patients with hospital acquired, including ventilator-associated, pneumonia failed[0m
[31mto demonstrate the efficacy of tigecycline for injection. TIGECYCLINE: warnings_and_cautions: In this trial, patients were randomized to receive tigecycline for injection [0m[1;31m([0m[1;31m100[0m[31m mg initially, then [0m[1;31m50[0m[31m mg[0m
[31mevery [0m[1;31m12[0m[31m hours[0m[1;31m)[0m[31m or a comparator. In addition, patients were allowed to receive specified adjunctive therapies. The sub-group of patients with ventilator-associated pneumonia who received tigecycline [0m
[31mfor injection had lower cure rates [0m[1;31m([0m[1;31m47.9[0m[31m% versus [0m[1;31m70.1[0m[31m% for the clinically evaluable population[0m[1;31m)[0m[31m. In this trial, greater mortality was seen in patients with ventilator-associated pneumonia who received[0m
[31mtigecycline for injection [0m[1;31m([0m[1;31m25[0m[31m/[0m[1;31m131[0m[31m [0m[1;31m[[0m[1;31m19.1[0m[31m%[0m[1;31m][0m[31m versus [0m[1;31m15[0m[31m/[0m[1;31m122[0m[31m [0m[1;31m[[0m[1;31m12.3[0m[31m%[0m[1;31m][0m[31m in comparator-treated patients[0m[1;31m)[0m[31m [0m[31m . Particularly high mortality was seen among tigecycline for injection-treated patients with [0m
[31mventilator-associated pneumonia and bacteremia at baseline [0m[1;31m([0m[1;31m9[0m[31m/[0m[1;31m18[0m[31m [0m[1;31m[[0m[1;31m50.0[0m[31m%[0m[1;31m][0m[31m versus [0m[1;31m1[0m[31m/[0m[1;31m13[0m[31m [0m[1;31m[[0m[1;31m7[0m[31m. TIGECYCLINE: warnings_and_cautions: [0m[1;31m7[0m[31m%[0m[1;31m][0m[31m in comparator-treated patients[0m[1;31m)[0m[31m. [0m[1;31m5.3[0m[31m Anaphylactic Reactions [0m
[31mAnaphylactic reactions have been reported with nearly all antibacterial agents, including tigecycline for injection, and may be life-threatening. Tigecycline for injection is structurally similar to [0m
[31mtetracycline-class antibacterial drugs and should be avoided in patients with known hypersensitivity to tetracycline-class antibacterial drugs. [0m[1;31m5.4[0m[31m Hepatic Adverse Effects Increases in total bilirubin[0m
[31mconcentration, prothrombin time and transaminases have been seen in patients treated with tigecycline. Isolated cases of significant hepatic dysfunction and hepatic failure have been reported in [0m
[31mpatients being treated with tigecycline. Some of these patients were receiving multiple concomitant medications.         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: pharm_class_cs         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: product_ndc         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: package_ndc         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: openfda: spl_id         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: warnings_and_cautions: If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and [0m
[31melectrolyte management, protein supplementation, antibacterial drug treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated. [0m[1;31m5.10[0m[31m Sepsis/Septic Shock in [0m
[31mPatients With Intestinal Perforation Monotherapy with tigecycline should be avoided in patients with complicated intra-abdominal infections [0m[1;31m([0m[31mcIAI[0m[1;31m)[0m[31m secondary to clinically apparent intestinal [0m
[31mperforation. In cIAI studies [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m1642[0m[1;31m)[0m[31m, [0m[1;31m6[0m[31m patients treated with tigecycline for injection and [0m[1;31m2[0m[31m patients treated with imipenem/cilastatin presented with intestinal perforations and developed [0m
[31msepsis/septic shock. TIGECYCLINE: warnings_and_cautions: The [0m[1;31m6[0m[31m patients treated with tigecycline for injection had higher APACHE II scores [0m[1;31m([0m[31mmedian = [0m[1;31m13[0m[1;31m)[0m[31m versus the [0m[1;31m2[0m[31m patients treated with [0m
[31mimipenem/cilastatin [0m[1;31m([0m[31mAPACHE II scores = [0m[1;31m4[0m[31m and [0m[1;31m6[0m[1;31m)[0m[31m. Due to differences in baseline APACHE II scores between treatment groups and small overall numbers, the relationship of this outcome to treatment [0m
[31mcannot be established. [0m[1;31m5.11[0m[31m Tetracycline-Class Adverse Effects Tigecycline for injection is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse effects. Such [0m
[31meffects may include: photosensitivity, pseudotumor cerebri, and anti-anabolic action [0m[1;31m([0m[31mwhich has led to increased BUN, azotemia, acidosis, and hyperphosphatemia[0m[1;31m)[0m[31m. [0m[1;31m5[0m[31m. TIGECYCLINE: warnings_and_cautions:[0m
[1;31m12[0m[31m Development of Drug-Resistant Bacteria Prescribing tigecycline for injection in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and [0m
[31mincreases the risk of the development of drug-resistant bacteria.         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: information_for_patients: [0m[1;31m17[0m[31m PATIENT COUNSELING INFORMATION Tooth Discoloration and Inhibition of Bone Growth Advise pregnant women that tigecycline for injection may cause [0m
[31mpermanent discoloration of deciduous teeth and reversible inhibition of bone growth when administered during the second and third trimesters of pregnancy [0m[31m. Lactation Advise a woman not to breastfeed [0m
[31mfor longer than [0m[1;31m3[0m[31m weeks while taking tigecycline for injection because of the lack of data on effects due to prolonged breastfeeding, and the theoretical risk of dental discoloration and inhibition of[0m
[31mbone growth. Women may also consider reducing infant exposure through pumping and discarding breastmilk during and for [0m[1;31m9[0m[31m days after the last dose of tigecycline [0m[31m. TIGECYCLINE: [0m
[31minformation_for_patients: Diarrhea Advise patients, their families, or caregivers that diarrhea is a common problem caused by antibacterial drugs, including tigecycline for injection. Sometimes, [0m
[31mfrequent watery or bloody diarrhea may occur and may be a sign of a more serious intestinal infection. If severe watery or bloody diarrhea develops, advise patients to contact his or her healthcare [0m
[31mprovider [0m[31m. Development of Resistance Patients should be counseled that antibacterial drugs including tigecycline for injection should only be used to treat bacterial infections. They do not treat [0m
[31mviral infections [0m[1;31m([0m[31me.g., the common cold[0m[1;31m)[0m[31m. When tigecycline for injection is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the [0m
[31mcourse of therapy, the medication should be taken exactly as directed. TIGECYCLINE: information_for_patients: Skipping doses or not completing the full course of therapy may [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m decrease the [0m
[31meffectiveness of the immediate treatment and [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m increase the likelihood that bacteria will develop resistance and will not be treatable by tigecycline for injection or other antibacterial drugs in [0m
[31mthe future. Manufactured by: Manufactured for: Gland Pharma Limited, India. Apotex Corp. ML No. TIGECYCLINE: information_for_patients: [0m[1;31m103[0m[31m/AP/RR/[0m[1;31m97[0m[31m/F/R Weston, Florida [0m[1;31m33326[0m[31m Revised: [0m[1;31m03[0m[31m/[0m[1;31m2021[0m[31m         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: pharmacokinetics: Gender In a pooled analysis of [0m[1;31m38[0m[31m women and [0m[1;31m298[0m[31m men participating in clinical pharmacology studies, there was no significant difference in the mean [0m[1;31m([0m[31m±SD[0m[1;31m)[0m[31m [0m
[31mtigecycline clearance between women [0m[1;31m([0m[1;31m20.7[0m[31m±[0m[1;31m6.5[0m[31m L/h[0m[1;31m)[0m[31m and men [0m[1;31m([0m[1;31m22.8[0m[31m±[0m[1;31m8.7[0m[31m L/h[0m[1;31m)[0m[31m. Therefore, no dosage adjustment is necessary based on gender. Race In a pooled analysis of [0m[1;31m73[0m[31m Asian subjects, [0m[1;31m53[0m[31m Black [0m
[31msubjects, [0m[1;31m15[0m[31m Hispanic subjects, [0m[1;31m190[0m[31m White subjects, and [0m[1;31m3[0m[31m subjects classified as “other” participating in clinical pharmacology studies, there was no significant difference in the mean [0m[1;31m([0m[31m±SD[0m[1;31m)[0m[31m [0m
[31mtigecycline clearance among the Asian subjects [0m[1;31m([0m[1;31m28.8[0m[31m±[0m[1;31m8.8[0m[31m L/h[0m[1;31m)[0m[31m, Black subjects [0m[1;31m([0m[1;31m23.0[0m[31m±[0m[1;31m7.8[0m[31m L/h[0m[1;31m)[0m[31m, Hispanic subjects [0m[1;31m([0m[1;31m24.3[0m[31m±[0m[1;31m6.5[0m[31m L/h[0m[1;31m)[0m[31m, White subjects [0m[1;31m([0m[1;31m22.1[0m[31m±[0m[1;31m8.9[0m[31m L/h[0m[1;31m)[0m[31m, and “other” subjects [0m[1;31m([0m[1;31m25[0m[31m. TIGECYCLINE: [0m
[31mpharmacokinetics: [0m[1;31m0[0m[31m±[0m[1;31m4.8[0m[31m L/h[0m[1;31m)[0m[31m. Therefore, no dosage adjustment is necessary based on race. Drug Interaction Studies Digoxin Tigecycline for injection [0m[1;31m([0m[1;31m100[0m[31m mg followed by [0m[1;31m50[0m[31m mg every [0m[1;31m12[0m[31m hours[0m[1;31m)[0m[31m and [0m
[31mdigoxin [0m[1;31m([0m[1;31m0.5[0m[31m mg followed by [0m[1;31m0.25[0m[31m mg, orally, every [0m[1;31m24[0m[31m hours[0m[1;31m)[0m[31m were co-administered to healthy subjects in a drug interaction study. Tigecycline slightly decreased the C max of digoxin by [0m[1;31m13[0m[31m%, but did [0m
[31mnot affect the AUC or clearance of digoxin. This small change in C max did not affect the steady-state pharmacodynamic effects of digoxin as measured by changes in ECG intervals. In addition, digoxin [0m
[31mdid not affect the pharmacokinetic profile of tigecycline. Therefore, no dosage adjustment of either drug is necessary when tigecycline for injection is administered with digoxin. TIGECYCLINE: [0m
[31mpharmacokinetics: Warfarin Concomitant administration of tigecycline for injection [0m[1;31m([0m[1;31m100[0m[31m mg followed by [0m[1;31m50[0m[31m mg every [0m[1;31m12[0m[31m hours[0m[1;31m)[0m[31m and warfarin [0m[1;31m([0m[1;31m25[0m[31m mg single-dose[0m[1;31m)[0m[31m to healthy subjects resulted in a decrease[0m
[31min clearance of R‑warfarin and S‑warfarin by [0m[1;31m40[0m[31m% and [0m[1;31m23[0m[31m%, an increase in C max by [0m[1;31m38[0m[31m% and [0m[1;31m43[0m[31m% and an increase in AUC by [0m[1;31m68[0m[31m% and [0m[1;31m29[0m[31m%, respectively. Tigecycline did not significantly alter the effects [0m
[31mof warfarin on INR. In addition, warfarin did not affect the pharmacokinetic profile of tigecycline. However, prothrombin time or other suitable anticoagulation test should be monitored if tigecycline[0m
[31mis administered with warfarin. TIGECYCLINE: pharmacokinetics: In vitro studies in human liver microsomes indicate that tigecycline does not inhibit metabolism mediated by any of the following [0m[1;31m6[0m[31m [0m
[31mcytochrome P450 [0m[1;31m([0m[31mCYP[0m[1;31m)[0m[31m isoforms: 1A2, 2C8, 2C9, 2C19, 2D6, and 3A4. Therefore, tigecycline for injection is not expected to alter the metabolism of drugs metabolized by these enzymes. In addition, [0m
[31mbecause tigecycline is not extensively metabolized, clearance of tigecycline is not expected to be affected by drugs that inhibit or induce the activity of these CYP450 isoforms. In vitro studies [0m
[31musing Caco-[0m[1;31m2[0m[31m cells indicate that tigecycline does not inhibit digoxin flux, suggesting that tigecycline is not a P-glycoprotein [0m[1;31m([0m[31mP-gp[0m[1;31m)[0m[31m inhibitor. TIGECYCLINE: pharmacokinetics: This in vitro [0m
[31minformation is consistent with the lack of effect of tigecycline on digoxin clearance noted in the in vivo drug interaction study described above. Tigecycline is a substrate of P-gp based on an in [0m
[31mvitro study using a cell line overexpressing P-gp. The potential contribution of P-gp-mediated transport to the in vivo disposition of tigecycline is not known. Coadministration of P-gp inhibitors [0m
[1;31m([0m[31me.g., ketoconazole or cyclosporine[0m[1;31m)[0m[31m or P-gp inducers [0m[1;31m([0m[31me.g., rifampicin[0m[1;31m)[0m[31m could affect the pharmacokinetics of tigecycline.         [0m
[31mSOURCE:TIGECYCLINE label[0m


[31mCONTENT: TIGECYCLINE: clinical_studies: [0m[1;31m3[0m[1;31m)[0m[31m Legionella pneumophila [0m[1;31m10[0m[31m/[0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m100.0[0m[1;31m)[0m[31m [0m[1;31m6[0m[31m/[0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m100.0[0m[1;31m)[0m[31m Streptococcus pneumoniae [0m[1;31m([0m[31mpenicillin-susceptible only[0m[1;31m)[0m[31m b [0m[1;31m44[0m[31m/[0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m95.7[0m[1;31m)[0m[31m [0m[1;31m39[0m[31m/[0m[1;31m44[0m[31m [0m[1;31m([0m[1;31m88.6[0m[1;31m)[0m[31m To further evaluate the [0m
[31mtreatment effect of tigecycline, a post-hoc analysis was conducted in CABP patients with a higher risk of mortality, for whom the treatment effect of antibacterial drugs is supported by historical [0m
[31mevidence. The higher-risk group included CABP patients from the two studies with any of the following factors: Age ≥[0m[1;31m50[0m[31m years PSI score ≥[0m[1;31m3[0m[31m Streptococcus pneumoniae bacteremia The results of this [0m
[31manalysis are shown in Table [0m[1;31m10[0m[31m. Age ≥[0m[1;31m50[0m[31m was the most common risk factor in the higher-risk group. Table [0m[1;31m10[0m[31m. TIGECYCLINE: clinical_studies: Post-hoc Analysis of Clinical Cure Rates in Patients with [0m
[31mCommunity-Acquired Bacterial Pneumonia Based on Risk of Mortality a Tigecycline for injection Levofloxacin n/N [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m n/N [0m[1;31m([0m[31m%[0m[1;31m)[0m[31m [0m[1;31m95[0m[31m% CI b a Patients at higher risk of death include patients with any one of [0m
[31mthe following: ≥[0m[1;31m50[0m[31m year of age; PSI score ≥[0m[1;31m3[0m[31m; or bacteremia due to Streptococcus pneumoniae b [0m[1;31m95[0m[31m% confidence interval for the treatment difference c After at least [0m[1;31m3[0m[31m days of intravenous therapy, a [0m
[31mswitch to oral levofloxacin [0m[1;31m([0m[1;31m500[0m[31m mg daily[0m[1;31m)[0m[31m was permitted for both treatment arms in Study [0m[1;31m1[0m[31m. Study [0m[1;31m1[0m[31m c CE Higher risk Yes [0m[1;31m93[0m[31m/[0m[1;31m103[0m[31m [0m[1;31m([0m[1;31m90.3[0m[1;31m)[0m[31m [0m[1;31m84[0m[31m/[0m[1;31m102[0m[31m [0m[1;31m([0m[1;31m82.4[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-2.3[0m[31m, [0m[1;31m18.2[0m[1;31m)[0m[31m No [0m[1;31m32[0m[31m/[0m[1;31m35[0m[31m [0m[1;31m([0m[1;31m91.4[0m[1;31m)[0m[31m [0m[1;31m52[0m[31m/[0m[1;31m54[0m[31m [0m[1;31m([0m[1;31m96.3[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-20.8[0m[31m, [0m
[1;31m7[0m[31m. TIGECYCLINE: clinical_studies: [0m[1;31m1[0m[1;31m)[0m[31m c-mITT Higher risk Yes [0m[1;31m111[0m[31m/[0m[1;31m142[0m[31m [0m[1;31m([0m[1;31m78.2[0m[1;31m)[0m[31m [0m[1;31m100[0m[31m/[0m[1;31m134[0m[31m [0m[1;31m([0m[1;31m74.6[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-6.9[0m[31m, [0m[1;31m14[0m[1;31m)[0m[31m No [0m[1;31m38[0m[31m/[0m[1;31m49[0m[31m [0m[1;31m([0m[1;31m77.6[0m[1;31m)[0m[31m [0m[1;31m58[0m[31m/[0m[1;31m69[0m[31m [0m[1;31m([0m[1;31m84.1[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-22.8[0m[31m, [0m[1;31m8.7[0m[1;31m)[0m[31m Study [0m[1;31m2[0m[31m CE Higher risk Yes [0m[1;31m95[0m[31m/[0m[1;31m107[0m[31m [0m[1;31m([0m[1;31m88.8[0m[1;31m)[0m[31m [0m[1;31m68[0m[31m/[0m[1;31m85[0m[31m [0m[1;31m([0m[1;31m80[0m[1;31m)[0m[31m [0m
[1;31m([0m[1;31m-2.2[0m[31m, [0m[1;31m20.3[0m[1;31m)[0m[31m No [0m[1;31m33[0m[31m/[0m[1;31m37[0m[31m [0m[1;31m([0m[1;31m89.2[0m[1;31m)[0m[31m [0m[1;31m48[0m[31m/[0m[1;31m51[0m[31m [0m[1;31m([0m[1;31m94.1[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-21.1[0m[31m, [0m[1;31m8.6[0m[1;31m)[0m[31m c-mITT Higher risk Yes [0m[1;31m112[0m[31m/[0m[1;31m134[0m[31m [0m[1;31m([0m[1;31m83.6[0m[1;31m)[0m[31m [0m[1;31m93[0m[31m/[0m[1;31m120[0m[31m [0m[1;31m([0m[1;31m77.5[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-4.2[0m[31m, [0m[1;31m16.4[0m[1;31m)[0m[31m No [0m[1;31m58[0m[31m/[0m[1;31m69[0m[31m [0m[1;31m([0m[1;31m84.1[0m[1;31m)[0m[31m [0m[1;31m70[0m[31m/[0m[1;31m80[0m[31m [0m[1;31m([0m[1;31m87.5[0m[1;31m)[0m[31m [0m[1;31m([0m[1;31m-16.2[0m[31m, [0m[1;31m8[0m[31m.         [0m
[31mSOURCE:TIGECYCLINE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Tigecycline has been associated with an increased risk of all-cause mortality compared to comparator drugs in clinical trials. Specifically, in a meta-analysis of Phase [0m[1;32m3[0m[32m and [0m[1;32m4[0m[32m clinical [0m
[32mtrials, death occurred in [0m[1;32m4.0[0m[32m% of patients receiving tigecycline and [0m[1;32m3.0[0m[32m% of patients receiving comparator drugs. The adjusted risk difference of all-cause mortality was [0m[1;32m0.6[0m[32m% between the two groups. [0m
[32mIn trials for approved indications, the adjusted mortality rate was [0m[1;32m2.5[0m[32m% for tigecycline and [0m[1;32m1.8[0m[32m% for comparator. Additionally, a trial of patients with hospital-acquired pneumonia, including [0m
[32mventilator-associated pneumonia, failed to demonstrate the efficacy of tigecycline, and greater mortality was seen in patients with ventilator-associated pneumonia who received tigecycline [0m[1;32m([0m[1;32m19.1[0m[32m% [0m
[32mversus [0m[1;32m12.3[0m[32m% in comparator-treated patients[0m[1;32m)[0m[32m. The cause of the mortality difference has not been established, but generally, deaths were the result of worsening infection, complications of infection, [0m
[32mor underlying comorbidities. Tigecycline should be reserved for use when alternative treatments are not suitable.[0m

[32mSOURCE: TIGECYCLINE label[0m
[32mEXTRACT_START_END: An increase in all-cause mortality [0m[32m...[0m[32m underlying co-morbidities.[0m
*[1m([0morchestrator-hospitalization-TIGECYCLINE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Tigecycline has been associated with an increased risk of [0m
[34mall-cause mortality compared to comparator drugs in clinical trials. Specifically, in a meta-analysis of Phase [0m[1;34m3[0m[34m and [0m[1;34m4[0m[34m clinical trials, death occurred in [0m[1;34m4.0[0m[34m% of patients receiving tigecycline and [0m
[1;34m3.0[0m[34m% of patients receiving comparator drugs. The adjusted risk difference of all-cause mortality was [0m[1;34m0.6[0m[34m% between the two groups. In trials for approved indications, the adjusted mortality rate was [0m
[1;34m2.5[0m[34m% for tigecycline and [0m[1;34m1.8[0m[34m% for comparator. Additionally, a trial of patients with hospital-acquired pneumonia, including ventilator-associated pneumonia, failed to demonstrate the efficacy of [0m
[34mtigecycline, and greater mortality was seen in patients with ventilator-associated pneumonia who received tigecycline [0m[1;34m([0m[1;34m19.1[0m[34m% versus [0m[1;34m12.3[0m[34m% in comparator-treated patients[0m[1;34m)[0m[34m. The cause of the mortality [0m
[34mdifference has not been established, but generally, deaths were the result of worsening infection, complications of infection, or underlying comorbidities. Tigecycline should be reserved for use when [0m
[34malternative treatments are not suitable.[0m

[34mSOURCE: TIGECYCLINE label[0m
[34mEXTRACT_START_END: An increase in all-cause mortality [0m[34m...[0m[34m underlying co-morbidities.[0m
 [1m([0morchestrator-hospitalization-TIGECYCLINE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hospitalization-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does TIGECYCLINE increase or decrease the risk of hospitalization?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether TIGECYCLINE increases or decreases the risk of hospitalization."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that TIGECYCLINE has been associated with an increased risk of all-cause mortality compared to comparator drugs in clinical trials, with a higher occurrence of death in [0m
[32mpatients receiving tigecycline. This information suggests that tigecycline may be associated with more severe outcomes, which could indirectly indicate an increased risk of hospitalization, although [0m
[32mthe direct correlation to hospitalization risk was not explicitly stated."[0m[32m,[0m
[32m      [0m[32m"The increased mortality was often due to worsening infection, complications of infection, or underlying comorbidities, and tigecycline should be reserved for use when alternative treatments are[0m
[32mnot suitable."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"TIGECYCLINE has been associated with an increased risk of all-cause mortality in clinical trials, which may indirectly suggest an increased risk of hospitalization due to worsening [0m
[32minfection, complications of infection, or underlying comorbidities. However, the FDA label data does not explicitly state the direct effect of tigecycline on hospitalization risk, so the degree of [0m
[32mreliability regarding the increase in hospitalization risk cannot be fully determined from this information alone."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hospitalization-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-hospitalization-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hospitalization-TIGECYCLINE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-hospitalization-TIGECYCLINE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does TIGECYCLINE increase or decrease the risk of hospitalization?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether TIGECYCLINE increases or decreases the risk of hospitalization."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that TIGECYCLINE has been associated with an increased risk of all-cause mortality compared to comparator drugs in clinical trials, with a higher occurrence of death in [0m
[34mpatients receiving tigecycline. This information suggests that tigecycline may be associated with more severe outcomes, which could indirectly indicate an increased risk of hospitalization, although [0m
[34mthe direct correlation to hospitalization risk was not explicitly stated."[0m[34m,[0m
[34m      [0m[34m"The increased mortality was often due to worsening infection, complications of infection, or underlying comorbidities, and tigecycline should be reserved for use when alternative treatments are[0m
[34mnot suitable."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"TIGECYCLINE has been associated with an increased risk of all-cause mortality in clinical trials, which may indirectly suggest an increased risk of hospitalization due to worsening [0m
[34minfection, complications of infection, or underlying comorbidities. However, the FDA label data does not explicitly state the direct effect of tigecycline on hospitalization risk, so the degree of [0m
[34mreliability regarding the increase in hospitalization risk cannot be fully determined from this information alone."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does TIGECYCLINE increase or decrease the risk of hospitalization?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether TIGECYCLINE increases or decreases the risk of hospitalization.[0m
[1;31m2[0m[31m. FDAHandler responded that TIGECYCLINE has been associated with an increased risk of all-cause mortality compared to comparator drugs in clinical trials, with a higher occurrence of death in [0m
[31mpatients receiving tigecycline. This information suggests that tigecycline may be associated with more severe outcomes, which could indirectly indicate an increased risk of hospitalization, although [0m
[31mthe direct correlation to hospitalization risk was not explicitly stated.[0m
[1;31m3[0m[31m. The increased mortality was often due to worsening infection, complications of infection, or underlying comorbidities, and tigecycline should be reserved for use when alternative treatments are not[0m
[31msuitable.[0m
[31m        -----[0m
[31m        Final answer: TIGECYCLINE has been associated with an increased risk of all-cause mortality in clinical trials, which may indirectly suggest an increased risk of hospitalization due to [0m
[31mworsening infection, complications of infection, or underlying comorbidities. However, the FDA label data does not explicitly state the direct effect of tigecycline on hospitalization risk, so the [0m
[31mdegree of reliability regarding the increase in hospitalization risk cannot be fully determined from this information alone.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided does not contain any logical flaws. The user has correctly inferred that an increased risk of all-cause mortality associated with TIGECYCLINE, as reported by [0m
[32mFDAHandler, could suggest an increased risk of hospitalization due to worsening infection or complications. However, the user also correctly acknowledges that the direct effect on hospitalization risk[0m
[32mis not explicitly stated, which is a reasonable conclusion given the information provided. The user has also appropriately expressed the strength of evidence and the limitations in determining the [0m
[32mmagnitude of the effect."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-hospitalization-TIGECYCLINE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided does not contain any logical flaws. The user has correctly inferred that an increased risk of all-cause mortality associated with TIGECYCLINE, as reported by [0m
[34mFDAHandler, could suggest an increased risk of hospitalization due to worsening infection or complications. However, the user also correctly acknowledges that the direct effect on hospitalization risk[0m
[34mis not explicitly stated, which is a reasonable conclusion given the information provided. The user has also appropriately expressed the strength of evidence and the limitations in determining the [0m
[34mmagnitude of the effect."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-hospitalization-TIGECYCLINE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided does not contain any logical flaws. The user has correctly inferred that an increased risk of all-cause mortality associated with TIGECYCLINE, as reported by [0m
[31mFDAHandler, could suggest an increased risk of hospitalization due to worsening infection or complications. However, the user also correctly acknowledges that the direct effect on hospitalization risk[0m
[31mis not explicitly stated, which is a reasonable conclusion given the information provided. The user has also appropriately expressed the strength of evidence and the limitations in determining the [0m
[31mmagnitude of the effect.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0morchestrator-hospitalization-TIGECYCLINE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-hospitalization-TIGECYCLINE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hospitalization-TIGECYCLINE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe final answer to the question [0m[32m"Does TIGECYCLINE increase or decrease the risk of hospitalization?"[0m[32m is that TIGECYCLINE has been associated with an increased risk of all-cause mortality in clinical [0m
[32mtrials, which may indirectly suggest an increased risk of hospitalization due to worsening infection, complications of infection, or underlying comorbidities. However, the FDA label data does not [0m
[32mexplicitly state the direct effect of tigecycline on hospitalization risk, so the degree of reliability regarding the increase in hospitalization risk cannot be fully determined from this information [0m
[32malone.[0m
